Lunai Bioworks Inc. Market Cap ($747.19K)
Market Cap & Net Worth: Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. market cap. Lunai Bioworks Inc. (NASDAQ:LNAI) has a market capitalization of $747.19K ($747.19K) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30840 globally and #6269 in its home market, demonstrating a -68.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lunai Bioworks Inc.'s stock price $0.16 by its total outstanding shares 4533890 (4.53 Million). Also see cash flow conversion of Lunai Bioworks Inc. for how efficiently the company converts equity into cash flow.
Lunai Bioworks Inc. Market Cap History (2025–2026)
Lunai Bioworks Inc. market cap history from 2025 to 2026. Data shows growth from $4.00 Million to $747.19K (0.00% CAGR). Check LNAI live share price for real-time trading data and today's change.
Lunai Bioworks Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lunai Bioworks Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Lunai Bioworks Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LNAI by Market Capitalization
Companies near Lunai Bioworks Inc. in the global market cap rankings as of November 3, 2026. Also see Lunai Bioworks Inc. assets under control for a full breakdown of the balance sheet.
Key companies related to Lunai Bioworks Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Lunai Bioworks Inc. (2025–2026)
Market capitalization of Lunai Bioworks Inc. from 2025 to today. Between 2025 and today, Lunai Bioworks Inc.'s market cap moved from $4.00 Million to $ 747.19K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $747.19K | -81.31% |
| 2025 | $4.00 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Lunai Bioworks Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $747.19K USD |
| MoneyControl | $747.19K USD |
| MarketWatch | $747.19K USD |
| marketcap.company | $747.19K USD |
| Reuters | $747.19K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more